Neoadjuvant atezolizumab prior to concurrent chemoradiotherapy appeared safe and showed encouraging progression free and overall survival for patients with unresectable stage III non-small cell lung cancer. https://ja.ma/3yexhlm
JAMA Oncology
Book and Periodical Publishing
Chicago, Illinois 35,087 followers
A member of the JAMA Network, which includes JAMA, 11 specialty journals, and JAMA Network Open.
About us
JAMA Oncology is published online weekly, every Thursday, and in 12 print/online issues a year. The journal receives more than 6.4 million annual article views and downloads. Without any author fees, all research articles are made free access online 12 months after publication on the website. In addition, the online version is freely available or nearly so to institutions in developing countries through the World Health Organization's HINARI program. JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. The journal’s acceptance rate is 13%. The median time to first decision is 2 days, and 50 days with review. The Journal Impact Factor is 28.4, one of the highest ranking among oncology journals. All articles are published online first. Mary L. (Nora) Disis, MD, Director of the UW Institute of Translational Health Science and the Center for Translational Medicine in Women's Health, is the editor in chief.
- Website
-
https://jamanetwork.com/journals/jamaoncology
External link for JAMA Oncology
- Industry
- Book and Periodical Publishing
- Company size
- 5,001-10,000 employees
- Headquarters
- Chicago, Illinois
- Founded
- 2015
- Specialties
- Oncology
Updates
-
Most viewed in the last 7 days from JAMA Oncology: What is the feasibility and tumor biological activity of neoadjuvant exercise therapy in men with localized prostate cancer? https://ja.ma/3YDiATN
-
Viewpoint discusses the importance of hormone deprivation–free survival as an end point for both men with prostate cancer and women with breast cancer. https://ja.ma/3SrxSXB
-
Cohort study including 660k women with unilateral breast cancer and followed up for 20 years found that bilateral mastectomy was associated with a statistically significant reduction of contralateral breast cancer risk but not breast cancer mortality. https://ja.ma/4cVucWq
-
Most viewed in the last 7 days from JAMA Oncology: Is waterpipe tobacco smoking associated with an increased risk of cancer mortality in Vietnam? https://ja.ma/3WcWUeg
-
Phase 2 nonrandomized controlled trial of bintrafusp alfa in patients with recurrent or metastatic cervical cancer met its primary end point, which may support the further exploration of bifunctional molecules, particularly those targeting TGF-β and PD-L1. https://ja.ma/3y2B4Cd
-
Patients with metastatic or advanced cancer treated at practices with higher National Quality Forum 0210 rates did not have improved survival. https://ja.ma/4cSlmIT
-
In patients with node-positive breast cancer, axillary recurrence after omission of axillary lymph node dissection was rare with no difference by type of surgery (sentinel lymph node biopsy with dual-tracer mapping vs targeted axillary dissection). https://ja.ma/3zW8Byw
-
Meta-analysis of 24 randomized controlled trials demonstrates an increased risk of cardiovascular events amongst patients with advanced and metastatic prostate cancer commencing androgen receptor signaling inhibitors. https://ja.ma/4fcYIMO
-
The 10-year interval between colonoscopy screenings for colorectal cancer (CRC) could be extended to 15 years in patients with no family history of CRC and negative findings on their first colonoscopy, finds matched cohort study. https://ja.ma/3Wb50Ed